Developer docs
API playgroundTry for free, no card

Search company profiles

Simsen Diagnostics

Full company profile

uuid000a9h8

Namestring
Simsen Diagnostics
Legal namestring
Simsen Diagnostics AB
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Simsen Diagnostics AB is a Swedish healthcare technology company founded in 2020 as a spin-out from Sahlgrenska Academy, headquartered at AstraZeneca's BioVentureHub in Mölndal. The company develops and commercialises SiMSen-Seq, a proprietary ultra-sensitive circulating tumor DNA (ctDNA) sequencing platform that uses molecular barcoding with unique molecular identifiers (UMIs) and error suppression chemistry to achieve parts-per-million sensitivity (approximately 0.001% panel-level VAF, ~0.01% per-variant). This capability is designed to detect minimal residual disease (MRD) and tumour recurrence months earlier than standard imaging, with published lead times of 114 days in metastatic breast cancer and up to 9 months in paediatric neuroblastoma.

The flagship product, Simsen Personal, is a tumour-informed personalised monitoring service that tracks 20-30 patient-specific variants identified from a baseline tumour sample over time, supporting MRD detection, treatment response assessment, and resistance tracking. The technology is offered through two delivery models: a full-service EU-based laboratory (samples shipped to Mölndal) and LabSuite, a reagent-kit and protocol-transfer model that enables hospital and research laboratories to run SiMSen-Seq on their own validated Illumina instruments. The portfolio is completed by matched Simsen Personal Baseline and Follow-up Collection Kits for plasma and FFPE sample acquisition.

Revenue is generated through per-sample ctDNA testing fees for the full-service lab, LabSuite reagent and panel-design sales for in-house deployment, and professional services for clinical trial assay design, monitoring, and co-publication. Customers span three primary segments: pharmaceutical sponsors and CROs running European oncology clinical trials (Orion Corporation, One-carbon Therapeutics, Buzzard Pharmaceuticals, Neogap Therapeutics); translational oncology research laboratories (Sahlgrenska University Hospital, RISE, an unnamed Swedish hospital); and premium private oncology clinics (Docrates Cancer Center in Finland). Operations are restricted to Europe (EU, EEA, and UK), with samples never leaving the region, supporting GDPR-native data handling and ISO 15189-compliant laboratory practices. The company is led by CEO Pontus Rehn (appointed 2024) and CTO Stefan Filges (co-author of the original SiMSen-Seq Nature Protocols publication), has raised 10 million SEK from Nordic Ignite, and operates with 1-10 employees. Products are currently offered for Research Use Only and revenue is not publicly disclosed.

Short descriptiontext

Simsen Diagnostics is a Swedish biotechnology company providing ultra-sensitive tumour-informed ctDNA monitoring for pharma clinical trials, translational research laboratories, and premium oncology clinics across Europe, using its proprietary SiMSen-Seq molecular barcoding technology delivered as a service or in-house kit.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGothenburg, Sweden
HQ citystring
Gothenburg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ctDNA sequencing, liquid biopsy, minimal residual disease, molecular diagnostics, tumour-informed monitoring
Industry4 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Liquid Biopsy Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1ctDNA Analysis Services
TypeManaged Services
Description

Laboratory services for ultra-sensitive circulating tumor DNA analysis, offered as tumour-informed MRD monitoring for clinical trials, research studies, and clinic patients. Revenue generated through per-sample testing fees with personalized panels.

simsendiagnostics.com
2LabSuite Kit Sales
TypeHardware Sales
Description

Sale of reagent kits and panel designs for hospital laboratories and research institutions to run SiMSen-Seq in-house on their own Illumina instruments.

simsendiagnostics.com
3Clinical Trial Partnerships
TypeProfessional Services
Description

Collaborative partnerships with pharmaceutical companies for ctDNA monitoring in drug trials, including assay design, sample analysis, and co-publication.

simsendiagnostics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Simsen Personal
Description

Patient-specific ctDNA monitoring solution for cancer detection and monitoring

simsendiagnostics.com
+2 more records
Core offering1 text field

Simsen Diagnostics provides ultra-sensitive tumour-informed ctDNA (circulating tumor DNA) monitoring for minimal residual disease (MRD) detection, using its proprietary SiMSen-Seq barcoded sequencing platform with unique molecular identifiers (UMIs) that achieves parts-per-million sensitivity (~0.001% VAF). The offering is delivered through two channels: a full-service EU-based laboratory model where customers ship samples for analysis, and LabSuite, where validated reagent kits and patient-specific panels are provided for customers to run SiMSen-Seq in-house on their own Illumina instruments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 0.001% VAF panel-level MRD sensitivity; per-variant ~0.01% sensitivity
+4 more records
Product overview1 text field

Simsen Diagnostics offers a unified portfolio anchored by Simsen® Personal, an ultra-sensitive tumour-informed ctDNA monitoring solution. The core technology is the proprietary SiMSen-Seq platform, which uses barcoded sequencing with unique molecular identifiers (UMIs) and error suppression to achieve approximately 0.001% VAF sensitivity (parts-per-million detection). Customers can access the technology through two delivery models: the full-service lab option (samples shipped to Simsen's EU-based laboratory for analysis and reporting) or LabSuite (Simsen-supplied reagent kits and patient-specific panels run in-house on the customer's own validated Illumina instruments). The portfolio also includes Simsen® Personal Collection Kits — a Baseline Kit for first-visit tumour tissue, matched normal, and initial ctDNA draws, and a Follow-up ctDNA Kit for subsequent monitoring timepoints. All offerings are provided for Research Use Only (RUO) and are not ISO 15189 accredited clinical services.

Product and service4 records
1Simsen® Personal
CategoryctDNA Monitoring Service
Description

Ultra-sensitive tumour-informed ctDNA monitoring solution for clinical trials, research laboratories, and private oncology clinics. Tracks 20-30 patient-specific variants for MRD detection and resistance tracking, enabling earlier relapse detection than imaging.

2LabSuite
CategoryReagent Kit / In-House Solution
Description

In-house sequencing kit enabling hospital and research laboratories to run SiMSen-Seq on their own validated Illumina instruments, with Simsen-designed patient-specific panels, reagent kits, and sample collection kits supplied. No major capital investment required for adoption.

3Simsen® Personal Baseline Collection Kit
CategorySample Collection Kit
Description

First-visit collection kit containing tumour tissue specimen box for FFPE sections, 2 × 10 mL Streck tubes for plasma, and 1 × 6 mL EDTA tube for matched normal control. Used to initiate personalized ctDNA panel design.

4Simsen® Personal Follow-up ctDNA Collection Kit
CategorySample Collection Kit
Description

Ongoing monitoring kit for patients already established with a Baseline kit. Contains 2 × 10 mL Streck tubes for ctDNA plasma draws at each monitoring timepoint. No tissue or matched normal required.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1One-carbon Therapeutics
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

Collaboration for ODIN Phase 1/2 clinical trial evaluating TH9619 (MTHFD1/2 inhibitor) in selected solid cancers. Simsen Personal provides ctDNA monitoring throughout the trial for dose escalation guidance.

simsendiagnostics.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Hospital laboratory partnership enabling implementation of tumour-informed ctDNA analysis in-house. First step in empowering hospital laboratories to deliver personalised cancer care with LabSuite solution.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-21
Description

Partnership for Phase IIa trial evaluating isunakinra (IL-1 inhibitor) with pembrolizumab in metastatic colorectal cancer. Simsen Personal monitors ctDNA as predictor of therapeutic response.

4Docrates Cancer Center
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-25
Description

Agreement allowing Finland's only private cancer hospital to use Simsen's personalised ctDNA analysis for patient monitoring. Docrates integrates Simsen Personal for early detection of recurring cancer and treatment effectiveness monitoring.

simsendiagnostics.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-27
Description

Ongoing collaboration for Phase I/II T-cell immunotherapy trial in colorectal cancer. Simsen Personal monitors 36 neoantigens per patient selected by Neogap's PIOR software, tracking each mutation over time.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-26
Description

Collaboration during First-in-Human Phase I study evaluating Orion's drug candidate ODM-212 in patients with advanced solid tumors. Simsen Personal monitors ctDNA to guide dose escalation and evaluate therapeutic potential.

7VGR/Sahlgrenska University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-23
Description

FIRM Liquid Biopsy project collaboration for monitoring immunotherapy response in lung cancer patients. Hospital serves as end user and requirement setter with clinical expertise in genetics.

simsendiagnostics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-23
Description

FIRM Liquid Biopsy project collaboration. RISE leads project management and provides expertise in medical technology and diagnostic products. Drive the project forward alongside Simsen.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Contract signed to evaluate Simsen's kit solution for potential distribution or partnership in sample collection kit provision.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Academic collaboration with research group studying gynecological cancers. Contract signed for new types of projects exploring Simsen's technology in this cancer area.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cergentis is a European molecular diagnostics company focused on tumor-informed ctDNA analysis for pharma trial MRD endpoints. Comparable to Simsen in geographic positioning, customer base (EU pharma), and platform approach.

TypeDirect peer
Description

Natera's Signatera is the leading commercial tumor-informed ctDNA MRD assay with identical application (personalized panels tracking patient-specific variants for MRD monitoring). Natera also offers a dual delivery model (central lab + EmpowerDx kit). It is the most direct competitor to Simsen Personal.

TypeEmerging player
Description

Hummingbird Bioscience is a clinical-stage biotech that integrates biomarker-driven patient selection into oncology trials. Comparable to Simsen in the pharma-trial biomarker/MRD endpoint use case where ctDNA monitoring is embedded in trial design for response and resistance tracking.

TypeBroad incumbent
Description

Exact Sciences (via Thrive/Oncodetect and acquired genomics assets) is developing competing MRD and multi-cancer detection assays. It is a large public diagnostics company with the capital and US commercial footprint to compete across Simsen's targeted use cases.

TypeDirect peer
Description

RaDaR is a tumor-informed personalized MRD assay developed by Inivata (now part of NeoGenomics) using similar personalized SNV-based panel design. Direct competitor to Simsen Personal in the EU and US pharma trial endpoint market.

TypeBroad incumbent
Description

PGDx (now part of Labcorp) offers tissue and liquid biopsy molecular diagnostics with EU IVDR-marked kits. Comparable to Simsen in the IVD-reagent channel via LabSuite and in pharma central lab services, but with broader oncology menu.

TypeBroad incumbent
Description

Guardant Health offers the Guardant360 liquid biopsy CDx and Guardant Reveal MRD product (tumor-informed, ~0.01% sensitivity). It is a major incumbent with substantially more capital, FDA relationships, and pharma trial partnerships across oncology indications directly overlapping Simsen's positioning.

TypeRegional player
Description

Sophia Genetics is a Swiss-European health data/analytics company offering molecular diagnostics interpretation and multimodal analytics for oncology, with extensive EU hospital penetration. Comparable as a European-based diagnostics platform serving pharma and hospitals across the same geography Simsen targets.

TypeEmerging player
Description

Foresight Diagnostics is an emerging MRD-focused liquid biopsy company developing ultra-sensitive ctDNA assays (e.g., Foresight CLARITY) with strong academic validation. Comparable to Simsen in stage and tumor-informed approach but with US presence and venture backing from Foresite Labs.

TypeBroad incumbent
Description

Resolution Bioscience (acquired by Agilent) offers NGS-based liquid biopsy kits for ctDNA analysis. Comparable to Simsen's LabSuite reagent-kit channel, serving pharma and research labs requiring validated NGS workflows on customer instruments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Simsen Diagnostics

Liquid Biopsy Diagnosticssimsendiagnostics.com

Simsen Diagnostics is a Swedish biotechnology company providing ultra-sensitive tumour-informed ctDNA monitoring for pharma clinical trials, translational research laboratories, and premium oncology clinics across Europe, using its proprietary SiMSen-Seq molecular barcoding technology delivered as a service or in-house kit.

What Simsen Diagnostics does

Simsen Diagnostics AB is a Swedish healthcare technology company founded in 2020 as a spin-out from Sahlgrenska Academy, headquartered at AstraZeneca's BioVentureHub in Mölndal. The company develops and commercialises SiMSen-Seq, a proprietary ultra-sensitive circulating tumor DNA (ctDNA) sequencing platform that uses molecular barcoding with unique molecular identifiers (UMIs) and error suppression chemistry to achieve parts-per-million sensitivity (approximately 0.001% panel-level VAF, ~0.01% per-variant). This capability is designed to detect minimal residual disease (MRD) and tumour recurrence months earlier than standard imaging, with published lead times of 114 days in metastatic breast cancer and up to 9 months in paediatric neuroblastoma.

The flagship product, Simsen Personal, is a tumour-informed personalised monitoring service that tracks 20-30 patient-specific variants identified from a baseline tumour sample over time, supporting MRD detection, treatment response assessment, and resistance tracking. The technology is offered through two delivery models: a full-service EU-based laboratory (samples shipped to Mölndal) and LabSuite, a reagent-kit and protocol-transfer model that enables hospital and research laboratories to run SiMSen-Seq on their own validated Illumina instruments. The portfolio is completed by matched Simsen Personal Baseline and Follow-up Collection Kits for plasma and FFPE sample acquisition.

Revenue is generated through per-sample ctDNA testing fees for the full-service lab, LabSuite reagent and panel-design sales for in-house deployment, and professional services for clinical trial assay design, monitoring, and co-publication. Customers span three primary segments: pharmaceutical sponsors and CROs running European oncology clinical trials (Orion Corporation, One-carbon Therapeutics, Buzzard Pharmaceuticals, Neogap Therapeutics); translational oncology research laboratories (Sahlgrenska University Hospital, RISE, an unnamed Swedish hospital); and premium private oncology clinics (Docrates Cancer Center in Finland). Operations are restricted to Europe (EU, EEA, and UK), with samples never leaving the region, supporting GDPR-native data handling and ISO 15189-compliant laboratory practices. The company is led by CEO Pontus Rehn (appointed 2024) and CTO Stefan Filges (co-author of the original SiMSen-Seq Nature Protocols publication), has raised 10 million SEK from Nordic Ignite, and operates with 1-10 employees. Products are currently offered for Research Use Only and revenue is not publicly disclosed.

Simsen Diagnostics firmographics

Firmographics
Name
Simsen Diagnostics
Legal name
Simsen Diagnostics AB
Website
https://simsendiagnostics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Simsen Diagnostics is a Swedish biotechnology company providing ultra-sensitive tumour-informed ctDNA monitoring for pharma clinical trials, translational research laboratories, and premium oncology clinics across Europe, using its proprietary SiMSen-Seq molecular barcoding technology delivered as a service or in-house kit.
Ownership category
akta.pro rank

Simsen Diagnostics industry classification

Industry
Product category
Liquid Biopsy Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • CtDNA sequencing
  • Liquid biopsy
  • Minimal residual disease
  • Molecular diagnostics
  • Tumour-informed monitoring

Where Simsen Diagnostics is headquartered

Location

Headquarters

HQ city
Gothenburg
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Simsen Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ctDNA Analysis Services: Laboratory services for ultra-sensitive circulating tumor DNA analysis, offered as tumour-informed MRD monitoring for clinical trials, research studies, and clinic patients. Revenue generated through per-sample testing fees with personalized panels.
  2. LabSuite Kit Sales: Sale of reagent kits and panel designs for hospital laboratories and research institutions to run SiMSen-Seq in-house on their own Illumina instruments.
  3. Clinical Trial Partnerships: Collaborative partnerships with pharmaceutical companies for ctDNA monitoring in drug trials, including assay design, sample analysis, and co-publication.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Simsen Diagnostics product offering

Product offering

Core offering

Simsen Diagnostics provides ultra-sensitive tumour-informed ctDNA (circulating tumor DNA) monitoring for minimal residual disease (MRD) detection, using its proprietary SiMSen-Seq barcoded sequencing platform with unique molecular identifiers (UMIs) that achieves parts-per-million sensitivity (~0.001% VAF). The offering is delivered through two channels: a full-service EU-based laboratory model where customers ship samples for analysis, and LabSuite, where validated reagent kits and patient-specific panels are provided for customers to run SiMSen-Seq in-house on their own Illumina instruments.

Product overview

Simsen Diagnostics offers a unified portfolio anchored by Simsen® Personal, an ultra-sensitive tumour-informed ctDNA monitoring solution. The core technology is the proprietary SiMSen-Seq platform, which uses barcoded sequencing with unique molecular identifiers (UMIs) and error suppression to achieve approximately 0.001% VAF sensitivity (parts-per-million detection). Customers can access the technology through two delivery models: the full-service lab option (samples shipped to Simsen's EU-based laboratory for analysis and reporting) or LabSuite (Simsen-supplied reagent kits and patient-specific panels run in-house on the customer's own validated Illumina instruments). The portfolio also includes Simsen® Personal Collection Kits — a Baseline Kit for first-visit tumour tissue, matched normal, and initial ctDNA draws, and a Follow-up ctDNA Kit for subsequent monitoring timepoints. All offerings are provided for Research Use Only (RUO) and are not ISO 15189 accredited clinical services.

Differentiator

Problem solved

Functional benefit

Brands

  • Simsen Personal: Patient-specific ctDNA monitoring solution for cancer detection and monitoring
  • SiMSen-Seq
  • LabSuite

Products and services

  • Simsen® Personal Ultra-sensitive tumour-informed ctDNA monitoring solution for clinical trials, research laboratories, and private oncology clinics. Tracks 20-30 patient-specific variants for MRD detection and resistance tracking, enabling earlier relapse detection than imaging.
  • LabSuite In-house sequencing kit enabling hospital and research laboratories to run SiMSen-Seq on their own validated Illumina instruments, with Simsen-designed patient-specific panels, reagent kits, and sample collection kits supplied. No major capital investment required for adoption.
  • Simsen® Personal Baseline Collection Kit First-visit collection kit containing tumour tissue specimen box for FFPE sections, 2 × 10 mL Streck tubes for plasma, and 1 × 6 mL EDTA tube for matched normal control. Used to initiate personalized ctDNA panel design.
  • Simsen® Personal Follow-up ctDNA Collection Kit Ongoing monitoring kit for patients already established with a Baseline kit. Contains 2 × 10 mL Streck tubes for ctDNA plasma draws at each monitoring timepoint. No tissue or matched normal required.

Quantifiable outcome

  • 0.001% VAF panel-level MRD sensitivity; per-variant ~0.01% sensitivity
  • +4 more outcomes

Companies that use Simsen Diagnostics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Simsen Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Simsen Diagnostics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major, core and minor.

  • One-carbon TherapeuticsmajorStrategic or Co-development Partner · 17 November 2025Collaboration for ODIN Phase 1/2 clinical trial evaluating TH9619 (MTHFD1/2 inhibitor) in selected solid cancers. Simsen Personal provides ctDNA monitoring throughout the trial for dose escalation guidance.
  • Swedish Hospital (unnamed)majorStrategic or Co-development Partner · 26 June 2025Hospital laboratory partnership enabling implementation of tumour-informed ctDNA analysis in-house. First step in empowering hospital laboratories to deliver personalised cancer care with LabSuite solution.
  • Buzzard PharmaceuticalsmajorStrategic or Co-development Partner · 21 February 2025Partnership for Phase IIa trial evaluating isunakinra (IL-1 inhibitor) with pembrolizumab in metastatic colorectal cancer. Simsen Personal monitors ctDNA as predictor of therapeutic response.
  • Docrates Cancer CentermajorChannel Partner/ Reseller/ Distributor · 25 October 2024Agreement allowing Finland's only private cancer hospital to use Simsen's personalised ctDNA analysis for patient monitoring. Docrates integrates Simsen Personal for early detection of recurring cancer and treatment effectiveness monitoring.
  • Neogap TherapeuticsmajorStrategic or Co-development Partner · 27 September 2024Ongoing collaboration for Phase I/II T-cell immunotherapy trial in colorectal cancer. Simsen Personal monitors 36 neoantigens per patient selected by Neogap's PIOR software, tracking each mutation over time.
  • Orion CorporationmajorStrategic or Co-development Partner · 26 June 2024Collaboration during First-in-Human Phase I study evaluating Orion's drug candidate ODM-212 in patients with advanced solid tumors. Simsen Personal monitors ctDNA to guide dose escalation and evaluate therapeutic potential.
  • VGR/Sahlgrenska University HospitalcoreStrategic or Co-development Partner · 23 April 2024FIRM Liquid Biopsy project collaboration for monitoring immunotherapy response in lung cancer patients. Hospital serves as end user and requirement setter with clinical expertise in genetics.
  • RISE Research Institutes of SwedencoreStrategic or Co-development Partner · 23 April 2024FIRM Liquid Biopsy project collaboration. RISE leads project management and provides expertise in medical technology and diagnostic products. Drive the project forward alongside Simsen.
  • BiovendorminorChannel Partner/ Reseller/ Distributor · 1 January 2024Contract signed to evaluate Simsen's kit solution for potential distribution or partnership in sample collection kit provision.
  • Sahlgrenska University Hospital (Gynecological Cancers Research Group)minorStrategic or Co-development Partner · 1 January 2024Academic collaboration with research group studying gynecological cancers. Contract signed for new types of projects exploring Simsen's technology in this cancer area.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Simsen Diagnostics competitors and assessment

Company assessment

Emerging players

  • Cergentis: Cergentis is a European molecular diagnostics company focused on tumor-informed ctDNA analysis for pharma trial MRD endpoints. Comparable to Simsen in geographic positioning, customer base (EU pharma), and platform approach.
  • Hummingbird Bioscience: Hummingbird Bioscience is a clinical-stage biotech that integrates biomarker-driven patient selection into oncology trials. Comparable to Simsen in the pharma-trial biomarker/MRD endpoint use case where ctDNA monitoring is embedded in trial design for response and resistance tracking.
  • Foresight Diagnostics: Foresight Diagnostics is an emerging MRD-focused liquid biopsy company developing ultra-sensitive ctDNA assays (e.g., Foresight CLARITY) with strong academic validation. Comparable to Simsen in stage and tumor-informed approach but with US presence and venture backing from Foresite Labs.

Direct peers

  • Natera: Natera's Signatera is the leading commercial tumor-informed ctDNA MRD assay with identical application (personalized panels tracking patient-specific variants for MRD monitoring). Natera also offers a dual delivery model (central lab + EmpowerDx kit). It is the most direct competitor to Simsen Personal.
  • NeoGenomics (RaDaR / Inivata): RaDaR is a tumor-informed personalized MRD assay developed by Inivata (now part of NeoGenomics) using similar personalized SNV-based panel design. Direct competitor to Simsen Personal in the EU and US pharma trial endpoint market.

Broad incumbents

  • Exact Sciences: Exact Sciences (via Thrive/Oncodetect and acquired genomics assets) is developing competing MRD and multi-cancer detection assays. It is a large public diagnostics company with the capital and US commercial footprint to compete across Simsen's targeted use cases.
  • Personal Genome Diagnostics (PGDx / Labcorp): PGDx (now part of Labcorp) offers tissue and liquid biopsy molecular diagnostics with EU IVDR-marked kits. Comparable to Simsen in the IVD-reagent channel via LabSuite and in pharma central lab services, but with broader oncology menu.
  • Guardant Health: Guardant Health offers the Guardant360 liquid biopsy CDx and Guardant Reveal MRD product (tumor-informed, ~0.01% sensitivity). It is a major incumbent with substantially more capital, FDA relationships, and pharma trial partnerships across oncology indications directly overlapping Simsen's positioning.
  • Resolution Bioscience (Agilent): Resolution Bioscience (acquired by Agilent) offers NGS-based liquid biopsy kits for ctDNA analysis. Comparable to Simsen's LabSuite reagent-kit channel, serving pharma and research labs requiring validated NGS workflows on customer instruments.

Regional players

  • Sophia Genetics: Sophia Genetics is a Swiss-European health data/analytics company offering molecular diagnostics interpretation and multimodal analytics for oncology, with extensive EU hospital penetration. Comparable as a European-based diagnostics platform serving pharma and hospitals across the same geography Simsen targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Simsen Diagnostics social profiles

Digital presence

Simsen Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Simsen Diagnostics leadership team

Management profile

Number of profiles

Profiles3 records

Simsen Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Simsen Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simsen Diagnostics

What does Simsen Diagnostics do?

Simsen Diagnostics provides ultra-sensitive tumour-informed ctDNA (circulating tumor DNA) monitoring for minimal residual disease (MRD) detection, using its proprietary SiMSen-Seq barcoded sequencing platform with unique molecular identifiers (UMIs) that achieves parts-per-million sensitivity (~0.001% VAF). The offering is delivered through two channels: a full-service EU-based laboratory model where customers ship samples for analysis, and LabSuite, where validated reagent kits and patient-specific panels are provided for customers to run SiMSen-Seq in-house on their own Illumina instruments.

Is Simsen Diagnostics a public or private company?

Simsen Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Simsen Diagnostics founded?

Simsen Diagnostics was founded in 2020. It employs 1 to 10 people.

Where is Simsen Diagnostics based?

Simsen Diagnostics is headquartered in Gothenburg, Sweden, in the Europe region.

How does Simsen Diagnostics make money?

Three revenue lines are on record. ctDNA Analysis Services are the primary driver. The others are labSuite Kit Sales and clinical Trial Partnerships.

Who are Simsen Diagnostics's main competitors?

Emerging players on record are Cergentis, Hummingbird Bioscience and Foresight Diagnostics. Direct peers are Natera and NeoGenomics (RaDaR / Inivata). Broad incumbents are Exact Sciences, Personal Genome Diagnostics (PGDx / Labcorp), Guardant Health and Resolution Bioscience (Agilent). Sophia Genetics is listed as a regional player.

Does Simsen Diagnostics have an API?

No public API is recorded for Simsen Diagnostics.

What industry is Simsen Diagnostics in?

Simsen Diagnostics's product category is Liquid Biopsy Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals